Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line

Oncogene volume 33, pages 977–985 (2014)Cite this article

Subjects

Abstract

Neuroblastoma arises from sympathoadrenal progenitors of the neural crest and expression of the neurotrophin receptor TrkB and its ligand, brain-derived neurotrophic factor (BDNF), is correlated with poor prognosis. Although activated TrkB signaling promotes a more aggressive phenotype in established neuroblastoma cell lines, whether TrkB signaling is sufficient to transform neural crest-derived cells has not been investigated. To address the role of TrkB signaling in malignant transformation, we removed two immunoglobulin-like domains from the extracellular domain of the full-length rat TrkB receptor to create a ΔIgTrkB that is constitutively active. In the pheochromocytoma-derived cell line PC12, ΔIgTrkB promotes differentiation by stimulating process outgrowth; however, in the rat neural crest-derived cell line NCM-1, ΔIgTrkB signaling produces a markedly transformed phenotype characterized by increased proliferation, anchorage-independent cell growth, anoikis resistance and matrix invasion. Furthermore, expression of ΔIgTrkB leads to the upregulation of many transcripts encoding cancer-associated genes including cyclind1, twist1 and hgf, as well as downregulation of tumor suppressors such as pten and rb1. In addition, ΔIgTrkB NCM-1 cells show a 21-fold increase in mRNA for MYCN, the most common genetic marker for a poor prognosis in neuroblastoma. When injected into NOD SCID mice, control GFP NCM-1 cells fail to grow whereas ΔIgTrkB NCM-1 cells form rapidly growing and invasive tumors necessitating euthanasia of all mice by 15 days post injection. In summary, these results indicate that activated TrkB signaling is sufficient to promote the formation of a highly malignant phenotype in neural crest-derived cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma. Lancet 2007; 369: 2106–2120.

    Article  CAS  PubMed  Google Scholar 

  2. Brodeur GM . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203–216.

    Article  CAS  PubMed  Google Scholar 

  3. Miller FD, Kaplan DR . Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 2001; 58: 1045–1053.

    Article  CAS  PubMed  Google Scholar 

  4. Reichardt LF . Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545–1564.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nakagawara A . Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998; 11: 115–124.

    CAS  PubMed  Google Scholar 

  6. Schramm A, Schulte JH, Astrahantseff K, Apostolov O, Limpt V, Sieverts H et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett 2005; 228: 143–153.

    Article  CAS  PubMed  Google Scholar 

  7. Straub JA, Sholler GL, Nishi R . Embryonic sympathoblasts transiently express TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in vitro. BMC Dev Biol 2007; 7: 10.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Reiff T, Tsarovina K, Majdazari A, Schmidt M, del Pino I, Rohrer H . Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons. J Neurosci 2010; 30: 905–915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ . Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995; 55: 1798–1806.

    CAS  PubMed  Google Scholar 

  10. Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, Liu XG, Azar CG et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 1997; 31: 49–55.

    Article  CAS  PubMed  Google Scholar 

  11. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM . Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759–767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kim CJ, Matsuo T, Lee KH, Thiele CJ . Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells. Am J Pathol 1999; 155: 1661–1670.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, Spengler BA et al. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 1996; 56: 3737–3742.

    CAS  PubMed  Google Scholar 

  14. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ . Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res 2002; 62: 6756–6763.

    CAS  PubMed  Google Scholar 

  15. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002; 62: 6462–6466.

    CAS  PubMed  Google Scholar 

  16. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM . Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002; 62: 1802–1808.

    CAS  PubMed  Google Scholar 

  17. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ . Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 2006; 66: 4249–4255.

    Article  CAS  PubMed  Google Scholar 

  18. Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, Perez P . TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Mol Cell Biol 2000; 20: 5908–5916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Greene LA, Tischler AS . Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 1976; 73: 2424–2428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kaplan DR, Martin-Zanca D, Parada LF . Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991; 350: 158–160.

    Article  CAS  PubMed  Google Scholar 

  21. Jian Z, Nonaka I, Hattori S, Nakamura S . Activation of Ras and protection from apoptotic cell death by BDNF in PC12 cells expressing TrkB. Cell Signal 1996; 8: 365–370.

    Article  CAS  PubMed  Google Scholar 

  22. Lo LC, Birren SJ, Anderson DJ . V-myc immortalization of early rat neural crest cells yields a clonal cell line which generates both glial and adrenergic progenitor cells. Dev Biol 1991; 145: 139–153.

    Article  CAS  PubMed  Google Scholar 

  23. Urschitz J, Kawasumi M, Owens J, Morozumi K, Yamashiro H, Stoytchev I et al. Helper-independent piggyBac plasmids for gene delivery approaches: strategies for avoiding potential genotoxic effects. Proc Natl Acad Sci USA 2010; 107: 8117–8122.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Singh RK, Lange TS, Kim K, Zou Y, Lieb C, Sholler GL et al. Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines. Bioorg Med Chem Lett 2007; 17: 5846–5852.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004; 6: 347–360.

    Article  CAS  PubMed  Google Scholar 

  26. Thullberg M, Stromblad S . Anchorage-independent cytokinesis as part of oncogenic transformation? Cell Cycle 2008; 7: 984–988.

    Article  CAS  PubMed  Google Scholar 

  27. Chiarugi P, Giannoni E . Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008; 76: 1352–1364.

    Article  CAS  PubMed  Google Scholar 

  28. McKenzie AJ, Campbell SL, Howe AK . Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS One 2011; 6: e26552.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L . The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. Carcinogenesis 2005; 26: 2105–2115.

    Article  CAS  PubMed  Google Scholar 

  30. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL et al. Epithelial-Mesenchymal Transition Induced by TNF-alpha Requires NF-kappaB-Mediated Transcriptional Upregulation of Twist1. Cancer Res 2012; 72: 1290–1300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Martin-Zanca D, Hughes SH, Barbacid M . A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986; 319: 743–748.

    Article  CAS  PubMed  Google Scholar 

  32. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS . Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430: 1034–1039.

    Article  CAS  PubMed  Google Scholar 

  33. Glass DJ, Nye SH, Hantzopoulos P, Macchi MJ, Squinto SP, Goldfarb M et al. TrkB mediates BDNF/NT-3-dependent survival and proliferation in fibroblasts lacking the low affinity NGF receptor. Cell 1991; 66: 405–413.

    Article  CAS  PubMed  Google Scholar 

  34. Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991; 66: 395–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cimmino F, Schulte JH, Zollo M, Koster J, Versteeg R, Iolascon A et al. Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. Oncogene 2009; 28: 2015–2023.

    Article  CAS  PubMed  Google Scholar 

  36. Yu Y, Zhang S, Wang X, Yang Z, Ou G . Overexpression of TrkB promotes the progression of colon cancer. APMIS 2010; 118: 188–195.

    Article  CAS  PubMed  Google Scholar 

  37. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010; 29: 2047–2059.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C et al. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer 2010; 10: 43.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009; 15: 3244–3250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Huang YT, Lai PC, Wu CC, Hsu SH, Cheng CC, Lan YF et al. BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells. Int J Oncol 2010; 36: 1469–1476.

    CAS  PubMed  Google Scholar 

  41. Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K et al. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 2011; 51: 10–19.

    Article  PubMed  Google Scholar 

  42. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004; 6: 625–630.

    Article  CAS  PubMed  Google Scholar 

  43. Liu C, Park M, Tsao MS . Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 1992; 7: 181–185.

    CAS  PubMed  Google Scholar 

  44. Tokunou M, Niki T, Eguchi K, Iba S, Tsuda H, Yamada T et al. c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 1451–1463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005; 113: 678–682.

    Article  CAS  PubMed  Google Scholar 

  46. Ramirez R, Hsu D, Patel A, Fenton C, Dinauer C, Tuttle RM et al. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2000; 53: 635–644.

    Article  CAS  Google Scholar 

  47. Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS . Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 1995; 147: 889–895.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Ramsay GM, Moscovici G, Moscovici C, Bishop JM . Neoplastic transformation and tumorigenesis by the human protooncogene MYC. Proc Natl Acad Sci USA 1990; 87: 2102–2106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Lugo TG, Witte ON . The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol 1989; 9: 1263–1270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Screaton RA, Penn LZ, Stanners CP . Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 1997; 137: 939–952.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2012; 32: 1059–1065.

    Article  PubMed  Google Scholar 

  52. De Bernardi B, Pianca C, Pistamiglio P, Veneselli E, Viscardi E, Pession A et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 2001; 19: 183–190.

    Article  CAS  PubMed  Google Scholar 

  53. De Bernardi B, Balwierz W, Bejent J, Cohn SL, Garre ML, Iehara T et al. Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer Lett 2005; 228: 283–299.

    Article  CAS  PubMed  Google Scholar 

  54. Plantaz D, Rubie H, Michon J, Mechinaud F, Coze C, Chastagner P et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients—results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996; 78: 311–319.

    Article  CAS  PubMed  Google Scholar 

  55. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111–1116.

    Article  CAS  PubMed  Google Scholar 

  56. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM . Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997; 16: 2985–2995.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM . Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984; 81: 4940–4944.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S et al. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol 2011; 68: 1057–1065.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Feldman JP, Goldwasser R, Mark S, Schwartz J, Orion I . A mathematical model for tumor volume evaluation using two dimensions. J Appl Quant Methods 2009; 4: 455–462.

    Google Scholar 

Download references

Acknowledgements

We would like to thank Felix Eckenstein, Andy McKenzie and Nourine Ahmed for technical assistance. We also thank Alan Howe for helpful comments on our manuscript and for assistance with the ‘donut’ assay. Portions of this work were performed in the DNA Analysis Facility at the Vermont Cancer Center and the Neuroscience COBRE Molecular Cellular Core at the University of Vermont. This work was funded by Alex’s Lemonade Foundation (RN); R21NS25788 (RN); P30RR032135 (COBRE); P30GM103498 (COBRE); 5P20RR024206 (SM); and R01GM083158-01A1 (SM).

Author information

Authors and Affiliations

  1. Department of Anatomy and Neurobiology and Neuroscience Graduate Program, University of Vermont, Burlington, VT, USA

    J DeWitt, V Ochoa & R Nishi

  2. Department of Anatomy, Biochemistry, and Physiology, John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA

    J Urschitz, M Elston & S Moisyadi

  3. Manoa BioSciences, Honolulu, HI, USA

    S Moisyadi

Authors
  1. J DeWitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Ochoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Urschitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Elston
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Moisyadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Nishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Nishi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeWitt, J., Ochoa, V., Urschitz, J. et al. Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line. Oncogene 33, 977–985 (2014). https://doi.org/10.1038/onc.2013.39

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.39

Keywords

This article is cited by

Search

Advanced search

Quick links